Intellia’s CRISPR Gene Therapy for Rare Disease Advances in Phase 3 Trial, Sun Pharma to Acquire Organon for $11.75B
Intellia Therapeutics reported that a single dose of its CRISPR-based gene editing therapy, lonvo-z, dramatically reduced swelling attacks in a Phase...
